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April 10, 20211st Editorial Decision
RE: Manuscript  #E21-02-0082 
TITLE: A Troponin T Variant Linked with Pediatric Dilated Cardiomyopathy Decreases Cardiac
Contract ility by Reducing the Coupling of Thin Filament Act ivat ion to Myosin and Calcium Binding 
Dear Dr. Greenberg: 
As you can see, the reviewers are overall support ive of your manuscript . However, both request
revisions that merit  a round of re-review. In my own reading, I am opt imist ic that  this can be




Molecular Biology of the Cell 
------------------------------------------------------------------------ 
Dear Dr. Greenberg, 
The review of your manuscript , referenced above, is now complete. The Monitoring Editor has
decided that your manuscript  is not acceptable for publicat ion at  this t ime, but may be deemed
acceptable after specific revisions are made, as described in the Monitoring Editor's decision let ter
above and the reviewer comments below. 
A reminder: Please do not contact  the Monitoring Editor direct ly regarding your manuscript . If you
have any quest ions regarding the review process or the decision, please contact  the MBoC Editorial
Office (mboc@ascb.org). 
When submit t ing your revision include a rebuttal let ter that  details, point-by-point , how the
Monitoring Editor's and reviewers' comments have been addressed. (The file type for this let ter
must be "rebuttal let ter"; do not include your response to the Monitoring Editor and reviewers in a
"cover let ter.") Please bear in mind that your rebuttal let ter will be published with your paper if it  is
accepted, unless you haveopted out of publishing the review history. 
Authors are allowed 180 days to submit  a revision. If this t ime period is inadequate, please contact
us at  mboc@ascb.org. 
Revised manuscripts are assigned to the original Monitoring Editor whenever possible. However,
special circumstances may preclude this. Also, revised manuscripts are often sent out for re-review,
usually to the original reviewers when possible. The Monitoring Editor may solicit  addit ional reviews
if it  is deemed necessary to render a completely informed decision. 
In preparing your revised manuscript , please follow the instruct ion in the Informat ion for Authors
(www.molbiolcell.org/info-for-authors). In part icular, to prepare for the possible acceptance of your
revised manuscript , submit  final, publicat ion-quality figures with your revision as described. 
To submit  the rebuttal let ter, revised manuscript , and figures, use this link: Link Not Available 
Please contact  us with any quest ions at  mboc@ascb.org. 
Thank you for submit t ing your manuscript  to Molecular Biology of the Cell. We look forward to
receiving your revised paper. 
Sincerely, 
Eric Baker 
Journal Product ion Manager 
MBoC Editorial Office 
mbc@ascb.org 
------------------------------------------------------------------------ 
Reviewer #1 (Remarks to the Author): 
The manuscript  by Barrick et  al invest igates the molecular and cellular effects of the R134G TnT
mutat ion that is associated with pediatric-onset DCM. The work represents a logical cont inuat ion
of invest igat ing cardiomyopathy-causing thin filament mutat ions, using a suite of techniques and
approaches out lined in previous research and review art icles from the Greenberg Lab. The paper is
well-writ ten and data acquisit ion impressively thorough. Overall, it  is nice manuscript  that  potent ially
extends our understanding of the R134G TnT variant beyond that of earlier studies. However,
there are a few major and minor concerns with the study in its current form: 
Major: IVM studies) The authors only report  pCa50 values, the calcium concentrat ion at  which RTFs
glide at  half-max speed, i.e. the calcium sensit ivity of RTF mot ility. The data presented in Fig 2 are
normalized. Showing non-normalized data would be very useful for readers. Report ing the Vmax
and the percent filaments moving (at  least  at  max and min Ca) is recommended. Since in Fig 5F, KT
at pCa 9 is significant ly higher for the mutant, are more filaments possibly mot ile at  low Ca? Would
this contradict  "hypocontract ility" for the variant? Or might a 5-fold increase in KT at  pCa 9 st ill be
insufficient  to act ivate more sliding RTFs? Presumably so, since it  is stated on line 199 (and
repeated in the discussion) that  "At pCa 9, the level of thin filament act ivat ion is low despite the
increased value of KT because most thin filaments adopt the blocked state."; however, these raw
motility data should be shown. Also, qualitat ively, the IVM data in Fig 2 would appear to show
no/lit t le difference in nH, yet  the nH is reduced in Fig 5F by nearly half that  of WT. This is a major
finding of the study. Was a difference in nH unresolvable via IVM? If so, why? If the KT at  saturat ing
Ca for the mutant is so much lower than control, would that reduce mutant RTF Vmax or percent
filaments moving at  pCa 4 relat ive to WT? Gangadharan et  al., 2017 did report  significant ly reduced
max, R134G thin filament-act ivated ATPase act ivity. Also, in Fig 2 there appears to be no IVM data
points collected above pCa 7.5? 
Line 122) "A mutat ion-induced decrease in myosin crossbridge detachment kinet ics would
decrease RTF mot ility by decreasing the t ime myosin spends in the strongly bound state." It  is
recommended that the authors carefully check if this is accurate. After several reads, the current
reviewer struggled with the statement. It  seems that decreased detachment kinet ics would
INCREASE the t ime myosin spends strongly bound, and hence the opposite would be true. If it  is
correct , the authors might provide addit ional informat ion to help clarify this sentence as well as add
appropriate citat ions. This would assist  the general MBoC readership who may lack the expert ise
needed to fully comprehend the argument, and also help them better understand the subsequent
sentence beginning on line 124. 
pCa 4 KT values and "biological significance") In certain instances the biological significance of
changes in part icular indices (e.g. KW, line 216) is downplayed. However, a significant ly lower KT at
exceedingly high, non-physiological Ca concentrat ions, using non-physiological "homozygous" pools
of mutant RTFs is reported as a potent ially important disease-driving mechanism. Perhaps any
not ion of "biological significance" should be tempered. Relatedly, the authors claim (line 222) that
"these molecular-level measurements demonstrate that the mutat ion induced decrease in calcium
sensit ivity observed in the in vit ro mot ility assay is primarily caused by 1) reduced coupling of
calcium binding to changes in t ropomyosin posit ioning, result ing in reduced occupancy of the open
state in the presence of calcium". However, this was not observed at  more physiological,
"biologically-significant" Ca (6.25) levels, where no stat ist ically significant difference in KTs was
found. 
While acknowledged as a limitat ion of the study, the lack of Ca handling/t ransient data for hiPSC-
derived CMs makes data interpretat ion difficult . The hypocontract ility and reduced
shortening/lengthening velocit ies may simply result  from tracking perturbed Ca behavior, which
brings into quest ion relevance of the cellular data. Hence, it  may be premature to claim that (line
281) "At the cellular scale, these molecular defects lead to hypocontract ility, which in turn causes
changes in cellular morphology and disrupts sarcomeric organizat ion." 
Line 346) "In vit ro measurements of t ropomyosin-TnT binding affinity revealed that the R134G
variant, along with several other DCM-causing mutat ions within the TnT N-terminal domain,
decreases the affinity of TnT for t ropomyosin (Gangadharan et  al., 2017)." Please check the
accuracy of this statement and, therefore, the subsequent arguments that follow. Gangadharan et
al., 2017 indeed determined if the mutat ion changed TnT's affinity for Tm in vit ro. The paper states
that "Strikingly, the HCM mutants in regions 92-144, R92L, K124N, and R130C, significant ly
decreased the binding affinity for Tm (Fig. 1A and Table 2), while the DCM mutants R134G and
R144W increased the affinity significant ly (Fig. 1B)." Thus, one may argue that based on
INCREASED affinity, the mutant TnT may stabilize Tm end-to-end bonds, which is seemingly
inconsistent with the decreased cooperat ivity shown here by Barrick et  al. 
Minor: Line 57) The authors state "DCM is often caused by point  mutat ions in proteins that regulate
cardiac muscle contract ion and mechanosensat ion, including troponin T (TnT)." "Often" may be
overstated. Perhaps provide some numbers/reference to support  this statement. 
Line 92) "Porcine cardiac act in is ident ical to human act in, and porcine cardiac myosin is 97%
ident ical to human..." Please change to "Porcine cardiac act in is ident ical to human CARDIAC act in,
and porcine cardiac myosin is 97% ident ical to human CARDIAC MYOSIN..." 
Line 109) "This result  suggests that the R134G variant might demonstrate decreased force per
sarcomere during a calcium transient..." The variant will not  demonstrate decreased force, the
myocytes expressing the variant might demonstrate decreased force. 
Line 146) "Unexpectedly, we found that R134G has increased calcium binding to TnC [pCa50 (WT)
= 6.29 {plus minus}
0.07, pCa50 (R134G) = 6.6 {plus minus}
0.1; p < .001] (Figure 4). Thus, the increased calcium binding sensit ivity seen in R134G cannot
explain the decrease in calcium sensit ivity observed in the mot ility assay (Figure 2)." How might this
discrepancy be explained? i.e. TnC-Ca affinity being high, yet  RTF-Ca sensit ivity low? Are there
other examples of this in the literature? If not , should/could this potent ial novel observat ion be
further invest igated? 
Line 156) "The blocked state, in which tropomyosin blocks the strong myosin-binding site on the
thin filament, is significant ly occupied only at  low calcium concentrat ions." This current ly reads as
though there is a separate strong vs weak S1 binding site on act in. 
Line 202) "We est imated the occupancy of each state from the equilibrium constants determined
for WT and R134G and found that R134G decreased the occupancy of myosin-bound states by
31% at pCa 4." Present ing all these data (percent B-, C-, M-state occupancies) would be useful. 
Line 451) "In addit ion, we used homozygous isogenic lines to facilitate the comparison between the
molecular and cellular levels, whereas pat ients are usually homozygous." Pat ients are not usually
homozygous. 
Overall, the discussion could be abbreviated as it  is quite repet it ive. 
Reviewer #2 (Remarks to the Author): 
This is an outstanding manuscript  that  reports on the effects of a DCM associated variant in
cardiac t roponin T (TnT-R134G). The authors have assembled an impressive array of biophysical
and physiological tools to study the mechanist ic underpinnings of pathology associated with this
mutat ion. I have a couple of suggest ions for the authors to consider: 
1) Lines 73-75: It  is ment ioned that there is a small number of pat ients carrying this variant - Are
there refs that the author can add to scient ifically support  this statement? Another interest ing
point  to consider is that  different amino acid subst itut ions have been reported in this specific
residue, e.g., R134H, R134S, R134C, R134P, R134Q and R134W (see clinvar). 
2) Line 130, 133 and 135: actomyosin should read acto-S1 or actomyosin S1. 
3) Lines 202-204: it  is stated that R134G decreased the occupancy of myosin-bound states by
31%. This finding is somehow similar to the one reported in J Biol Chem. 2010 Jun 4;285(23):17371-
9. doi: 10.1074/jbc.M109.064105. How does the decreased occupancy of myosin bound states
compare to the maximum speed in the in vit ro mot ility assay? The JBC 2010 paper showed that the
reduct ion of the number of myosin binding site in the TF caused by a t roponin DCM mutat ion is
comparable to the reduct ion of force of contract ion and ATPase act ivat ion. 
4) Lines 206-214: to which figure is this paragraph referring? 
5) In figure 6, I am wondering if the R134G cells display more sarcomeres compared to WT and what
their diastolic sarcomere length are. 
6) Line 302: I think two log units for physiological calcium transients is too large of a range. Calcium
fluctuat ions in intact  cardiac myocytes is in the range of 0.1 - 1 microM. 
7) Lines 340-342: the following reference should be added to the sentence that describes TnT
interact ion with t ropomyosin filaments on both side of the filament: Proc Nat l Acad Sci U S A. 2021
Mar 30;118(13):e2024288118. doi: 10.1073/pnas.2024288118. 
8) It  is difficult  to reconcile increased TF calcium binding affinity with impaired tropomyosin posit ion
to more act ive state. Is it  possible that the R134G troponin complex is dissociat ing from act in-
t ropomyosin during the calcium t it rat ions since troponin complex has a higher calcium binding
affinity compared to TF?

May 27, 20211st Revision - authors' response
We thank the reviewers for their supportive comments and constructive suggestions. We have 
provided our point-by-point responses to the reviewer’s comments (reproduced in italics) below. 
The line numbers refer to the newly submitted manuscript. We are pleased to submit our revised 
manuscript for your consideration. 
 
Reviewer #1 (Remarks to the Author): 
  
The manuscript by Barrick et al investigates the molecular and cellular effects of the R134G TnT 
mutation that is associated with pediatric-onset DCM. The work represents a logical 
continuation of investigating cardiomyopathy-causing thin filament mutations, using a suite of 
techniques and approaches outlined in previous research and review articles from the 
Greenberg Lab. The paper is well-written and data acquisition impressively thorough. Overall, it 
is nice manuscript that potentially extends our understanding of the R134G TnT variant beyond 
that of earlier studies. However, there are a few major and minor concerns with the study in its 
current form:  
 
We thank the reviewer for their enthusiasm. 
 
Major: IVM studies) The authors only report pCa50 values, the calcium concentration at which 
RTFs glide at half-max speed, i.e. the calcium sensitivity of RTF motility. The data presented in 
Fig 2 are normalized. Showing non-normalized data would be very useful for readers. Reporting 
the Vmax and the percent filaments moving (at least at max and min Ca) is recommended.  
 
We thank the reviewer for the insightful suggestions. We now include the raw motility 
data and measurement of Vmax (new Fig. 2B). Also, we now report the percent stuck 
filaments at pCa 4 and 9 (new Fig. 2A).  
 
Since in Fig 5F, KT at pCa 9 is significantly higher for the mutant, are more filaments possibly 
motile at low Ca? Would this contradict "hypocontractility" for the variant? Or might a 5-fold 
increase in KT at pCa 9 still be insufficient to activate more sliding RTFs? Presumably so, since 
it is stated on line 199 (and repeated in the discussion) that "At pCa 9, the level of thin filament 
activation is low despite the increased value of KT because most thin filaments adopt the blocked 
state."; however, these raw motility data should be shown.  
 
Based on the reviewer’s suggestion, we quantified the percent stuck filaments at pCa 4 
and 9, and we do not see a difference at pCa 9 (p = 0.91, new figure 2A). This is 
consistent with our proposal that the increase in KT at pCa 9 has little effect on thin 
filament activation.  We now highlight this point on lines 331-337: 
“At low calcium (pCa 9), the larger value of KT for R134G signifies increased thin 
filament activation relative to WT; however, the overall level of activation for both WT 
and R134G is low since both KB and KT are small (≤0.3), indicating that most of the 
regulatory units are in the blocked state. Consistent with this observation, the fraction of 
stuck filaments in the in vitro motility assay at pCa 9 is the same for both the WT and 
mutant troponin. Therefore, the increase in KT at pCa 9 is not sufficient to explain the 
increase the motility of RTFs containing R134G troponin (Figure 2).” 
 
 
Also, qualitatively, the IVM data in Fig 2 would appear to show no/little difference in nH, yet the 
nH is reduced in Fig 5F by nearly half that of WT. This is a major finding of the study. Was a 
difference in nH unresolvable via IVM? If so, why?  
 
We did not detect a significant difference in nH from the motility data; however, the Hill 
coefficient is not well-resolved from the fit, as indicated by wide confidence intervals. In 
contrast, the pCa50 values are well-defined by the fit. Therefore, we are not confident in 
our ability to resolve differences in nH from our data. We now report the nH values in the 
text on lines 115-116.  We also note the challenges comparing the cooperativity measured 
in different assays on lines 366-375: 
“Our measurements also revealed a decrease in the cooperativity of myosin binding to 
thin filaments regulated by R134G TnT, relative to WT. This is important because full 
thin filament activation depends on both calcium and myosin binding (Houmeida et al., 
2010). This finding is qualitatively consistent with the decreased Hill coefficient of 
actomyosin ATPase activity observed for R134G TnT relative to WT (Gangadharan et 
al., 2017). While we did not observe a statistically significant change in the Hill 
coefficient in the motility assay, this could be due to the large uncertainty in determining 
this value.  Moreover, it should be noted that the Hill coefficients measured for motility, 




If the KT at saturating Ca for the mutant is so much lower than control, would that reduce 
mutant RTF Vmax or percent filaments moving at pCa 4 relative to WT? Gangadharan et al., 
2017 did report significantly reduced max, R134G thin filament-activated ATPase activity.  
 
We see a decrease in Vmax for the mutant relative to WT (new Fig. 2B) and an increase in 
the percent stuck filaments at pCa 4 (new Fig. 2A). Moreover, we found that the ADP 
release rates (Fig. 3) were the same for WT and R134G.  Therefore, the change in 
motility speed is likely due to changes in attachment kinetics (limited by the rate of 
phosphate release and strong binding) rather than detachment kinetics (limited by the rate 
of ADP release). This makes sense because regulatory proteins gate the association of 
myosin and the thin filament.  Therefore, our results are consistent with the studies of 
Gangadharan et al., who saw decreased ATPase activity, indicative of a slower rate of 
phosphate release and strong binding for R134G regulated thin filaments. We now 
highlight this point on lines 344-353: 
“A mutation-induced reduction in thin filament activation at saturating calcium 
concentrations may also help explain the shift in calcium sensitivity of RTF motility 
(Figure 2). The motility rate in the absence of regulatory proteins is frequently assumed 
to be limited by the rate of actomyosin dissociation (Huxley, 1990); however, we do not 
observe a change in the rate of ADP release with the mutant protein (Figure 3). 
Therefore, it is likely that the mutant is affecting attachment kinetics, which is reasonable 
since the transition to strong binding is regulated by troponin and tropomyosin. 
Therefore, the reduced maximal speed in the motility assay is consistent with the reduced 
actin-activated ATPase rate measured with R134G regulated thin filaments at fully 
activating calcium concentrations (Gangadharan et al., 2017).” 
 
Also, in Fig 2 there appears to be no IVM data points collected above pCa 7.5? 
  
We collected IVM data over the range of pCa 9-4. The measurements at pCa > 6.5 are 
perhaps not clear from the figure because we did not observe gliding filaments at these 
low calcium concentrations. As described in the methods, we assigned a speed of 0 to 
calcium concentrations that did not support continuous, directional filament gliding; thus, 
there are no error bars associated with these measurements. We have updated the figures 
to enlarge these points; however, they are partially obscured by the fitted line. We now 
mention that points collected at pCa 6.75, 7, 8, and 9 are likely obscured by the line. We 
have also edited the text to explicitly address the measurements at low calcium values on 
lines 568-570. 
 
Line 122) "A mutation-induced decrease in myosin crossbridge detachment kinetics would 
decrease RTF motility by decreasing the time myosin spends in the strongly bound state." It is 
recommended that the authors carefully check if this is accurate. After several reads, the current 
reviewer struggled with the statement. It seems that decreased detachment kinetics would 
INCREASE the time myosin spends strongly bound, and hence the opposite would be true. If it is 
correct, the authors might provide additional information to help clarify this sentence as well as 
add appropriate citations. This would assist the general MBoC readership who may lack the 
expertise needed to fully comprehend the argument, and also help them better understand the 
subsequent sentence beginning on line 124.  
 
We thank the reviewer for pointing this out. We have edited the manuscript to correct this 
typographical error and to further explain our logic. The sentence (lines 138-140) now 
reads, “A mutation-induced increase in the rate of myosin crossbridge detachment would 
decrease thin filament activation by decreasing the time myosin spends in the activating, 
strongly-bound state.” 
 
pCa 4 KT values and "biological significance") In certain instances the biological significance 
of changes in particular indices (e.g. KW, line 216) is downplayed. However, a significantly 
lower KT at exceedingly high, non-physiological Ca concentrations, using non-physiological 
"homozygous" pools of mutant RTFs is reported as a potentially important disease-driving 
mechanism. Perhaps any notion of "biological significance" should be tempered. Relatedly, the 
authors claim (line 222) that "these molecular-level measurements demonstrate that the mutation 
induced decrease in calcium sensitivity observed in the in vitro motility assay is primarily caused 
by 1) reduced coupling of calcium binding to changes in tropomyosin positioning, resulting in 
reduced occupancy of the open state in the presence of calcium". However, this was not observed 
at more physiological, "biologically-significant" Ca (6.25) levels, where no statistically 
significant difference in KTs was found. 
 
We appreciate the reviewer’s point and we have removed the reference to biological 
significance in this section.  We also now state (lines 354-357): “Although pCa 9 and 4 
are extreme values relative to the typical range of calcium concentrations in a 
physiological calcium transient, pCa 6-7 (Bers, 2002), we believe that measurements at 
pCa 9 and 4 provide meaningful insight into relaxed and fully activated conditions, 
respectively.” 
 
While acknowledged as a limitation of the study, the lack of Ca handling/transient data for 
hiPSC-derived CMs makes data interpretation difficult. The hypocontractility and reduced 
shortening/lengthening velocities may simply result from tracking perturbed Ca behavior, which 
brings into question relevance of the cellular data. Hence, it may be premature to claim that 
(line 281) "At the cellular scale, these molecular defects lead to hypocontractility, which in turn 
causes changes in cellular morphology and disrupts sarcomeric organization." 
 
We agree that the cellular data are consistent with molecular hypocontractility but do not 
unambiguously demonstrate that the molecular defects are the direct cause of the cellular 
hypocontractility. We have edited the manuscript to carefully make this distinction.  
These changes can be found on lines 413-416: 
“Our molecular studies suggest that the initial molecular insult driving disease 
pathogenesis is altered thin filament regulation that decreases thin filament activation, 
which is consistent with the decreased sarcomeric contractility observed in our stem cell-
derived cardiomyocyte model of R134G”. 
 
Line 346) "In vitro measurements of tropomyosin-TnT binding affinity revealed that the R134G 
variant, along with several other DCM-causing mutations within the TnT N-terminal domain, 
decreases the affinity of TnT for tropomyosin (Gangadharan et al., 2017)." Please check the 
accuracy of this statement and, therefore, the subsequent arguments that follow. Gangadharan et 
al., 2017 indeed determined if the mutation changed TnT's affinity for Tm in vitro. The paper 
states that "Strikingly, the HCM mutants in regions 92-144, R92L, K124N, and R130C, 
significantly decreased the binding affinity for Tm (Fig. 1A and Table 2), while the DCM 
mutants R134G and R144W increased the affinity significantly (Fig. 1B)." Thus, one may argue 
that based on INCREASED affinity, the mutant TnT may stabilize Tm end-to-end bonds, which is 
seemingly inconsistent with the decreased cooperativity shown here by Barrick et al.  
 
We thank the reviewer for correcting this error. The DCM mutants were associated with 
increased affinity for tropomyosin, as the reviewer correctly points out. However, it is not 
clear that this effect is inconsistent with decreased cooperativity of myosin binding to 
RTFs. We feel that the most important point is that TnT mutants can affect the Tm end-
to-end bonds, and we do not attempt to predict or explain the direction of this effect. 
 
Minor: Line 57) The authors state "DCM is often caused by point mutations in proteins that 
regulate cardiac muscle contraction and mechanosensation, including troponin T (TnT)." 
"Often" may be overstated. Perhaps provide some numbers/reference to support this statement.  
 
We have updated this statement (lines 57-59) to clarify that familial DCM is often caused 
by mutations in genes involved in contraction and mechanosensation. We have also 
added a reference regarding identified genetic causes of DCM. 
 
Line 92) "Porcine cardiac actin is identical to human actin, and porcine cardiac myosin is 97% 
identical to human..." Please change to "Porcine cardiac actin is identical to human CARDIAC 




Line 109) "This result suggests that the R134G variant might demonstrate decreased force per 
sarcomere during a calcium transient..." The variant will not demonstrate decreased force, the 




Line 156) "The blocked state, in which tropomyosin blocks the strong myosin-binding site on the 
thin filament, is significantly occupied only at low calcium concentrations." This currently reads 
as though there is a separate strong vs weak S1 binding site on actin. 
 
We have made the requested changes to the manuscript.  
 
Line 146) "Unexpectedly, we found that R134G has increased calcium binding to TnC [pCa50 
(WT) = 6.29 {plus/minus} 0.07, pCa50 (R134G) = 6.6 {plus minus} 
0.1; p < .001] (Figure 4). Thus, the increased calcium binding sensitivity seen in R134G cannot 
explain the decrease in calcium sensitivity observed in the motility assay (Figure 2)." How might 
this discrepancy be explained? i.e. TnC-Ca affinity being high, yet RTF-Ca sensitivity low? Are 
there other examples of this in the literature? If not, should/could this potential novel 
observation be further investigated? 
 
We agree that this is an interesting result, directly demonstrating reduced coupling between 
calcium binding to troponin C and activation of the thin filament. To the best of our 
knowledge, our observation of increased calcium binding affinity with decreased thin 
filament activation is a novel mechanism. That being said, the concept that cardiomyopathy 
mutations in the troponin T tail region can allosterically affect calcium binding and/or the 
coupling between the troponin complex and tropomyosin was proposed by the Tardiff group 
(e.g., PMID: 26957598 and PMID: 31387947). We have included discussion of this 
important point on lines 309-319:  
“The R134G variant decreased the calcium sensitivity of RTF motility (Figure 2) despite the 
increased affinity of TnC for calcium within RTFs containing R134G TnT, relative to WT 
(Figure 4). The effect of a mutation in TnT on calcium binding by TnC is consistent with 
previous work showing that two mutations at the R92 position of troponin T differentially 
altered calcium binding through a complex network of allosteric interactions (Williams et al., 
2016). Our data suggest that the R134G mutation alters allosteric communication among thin 
filament proteins such that the coupling between tropomyosin positioning and calcium 
binding to troponin C is reduced. This is consistent with a study showing that the nearby 
hypertrophic cardiomyopathy mutation ΔE160 can affect the coupling between the troponin 
core complex and the tropomyosin overlap region (Abdullah et al., 2019).”  
 
Line 202) "We estimated the occupancy of each state from the equilibrium constants determined 
for WT and R134G and found that R134G decreased the occupancy of myosin-bound states by 
31% at pCa 4." Presenting all these data (percent B-, C-, M-state occupancies) would be useful.  
 
We initially provided this estimate to give a more intuitive description of the magnitude 
of the mutation’s effect, compared to the observed change in KT. However, our estimates 
of the occupancy of each state from the determined equilibrium constants did not 
consider the cooperativity of thin filament activation. Upon further reflection, this 
simplification is unjustified given the effect of R134G on thin filament cooperativity, 
such that attempting to quantify state occupancies may be misleading. We have therefore 
removed the numerical estimate for occupancy of the myosin-bound states. 
 
Line 451) "In addition, we used homozygous isogenic lines to facilitate the comparison between 
the molecular and cellular levels, whereas patients are usually homozygous." Patients are not 
usually homozygous. 
 
We have corrected this typographical error.  
 
Overall, the discussion could be abbreviated as it is quite repetitive. 
  




Reviewer #2 (Remarks to the Author): 
  
This is an outstanding manuscript that reports on the effects of a DCM associated variant in 
cardiac troponin T (TnT-R134G). The authors have assembled an impressive array of 
biophysical and physiological tools to study the mechanistic underpinnings of pathology 
associated with this mutation. I have a couple of suggestions for the authors to consider: 
  
We thank the reviewer for their enthusiasm and support. 
 
1) Lines 73-75: It is mentioned that there is a small number of patients carrying this variant - 
Are there refs that the author can add to scientifically support this statement? Another 
interesting point to consider is that different amino acid substitutions have been reported in this 
specific residue, e.g., R134H, R134S, R134C, R134P, R134Q and R134W (see clinvar). 
 
We thank the reviewer for bringing this interesting point to our attention. The small 
number of patients referred to the study conducted by Hershberger et al. We have edited 
this statement to clarify that there is a small number of patients known to carry this 
specific mutation. We thank the reviewer for raising the interesting point about different 
mutations at this same position. We now discuss this point on lines 70-80: “…we 
examined the molecular and cellular consequences of a variant in troponin T, R134G, 
which has been implicated in pediatric-onset DCM (Hershberger et al., 2008) (Figure 1). 
Several variants at the R134 position have been implicated in cardiomyopathy, with 
clinical significance of individual variants ranging from uncertain to likely pathogenic 
(Landrum et al., 2018). We chose to study the likely pathogenic R134G variant, which 
was shown to segregate with DCM in a patient cohort (Hershberger et al., 2009). The 
small number of patients known to carry this specific variant makes it difficult to 
definitively determine pathogenicity from the currently available clinical data 
(Hershberger et al., 2009; Landrum et al., 2018).” 
  
2) Line 130, 133 and 135: actomyosin should read acto-S1 or actomyosin S1. 
 
We thank the reviewer for improving the precision of the language in the manuscript. We 
have edited the manuscript to specify actomyosin S1 when referencing experimental 
results. In the sentence extrapolating the results of our biochemical experiments (utilizing 
S1) to the in vitro motility assay (which utilizes full-length myosin), we have retained the 
original phrasing for simplicity. 
  
3) Lines 202-204: it is stated that R134G decreased the occupancy of myosin-bound states by 
31%. This finding is somehow similar to the one reported in J Biol Chem. 2010 Jun 
4;285(23):17371-9. doi: 10.1074/jbc.M109.064105. How does the decreased occupancy of 
myosin bound states compare to the maximum speed in the in vitro motility assay? The JBC 2010 
paper showed that the reduction of the number of myosin binding site in the TF caused by a 
troponin DCM mutation is comparable to the reduction of force of contraction and ATPase 
activation. 
 
We thank the reviewer for pointing out this reference, which we have included in support 
of the concept of reduced contractility due to fewer accessible binding sites. In our 
revised manuscript, we now show the absolute change in motility speed (new Fig. 2B) in 
addition to the normalized speed. Consistent with the reviewer’s suggestion, we see a 
reduction in the maximal speed in the motility assay, and we now discuss this point in the 
revised manuscript in both the results (lines 113-115) and the discussion (lines 204-218). 
 
In terms of the quantitative change seen in myosin-bound states, we have removed our 
attempt to quantify the decrease in occupancy of myosin-bound states in the manuscript 
due to our concern that our calculation did not appropriately account for changes in thin 
filament cooperativity. Please see our response to reviewer 1 for more details. 
  
4) Lines 206-214: to which figure is this paragraph referring? 
 
This paragraph is also referring to Figure 5. We apologize for the confusion and have 
added the appropriate figure reference. 
  
5) In figure 6, I am wondering if the R134G cells display more sarcomeres compared to WT and 
what their diastolic sarcomere length are. 
 
We thank the reviewer for this interesting question. Based on the reviewer’s question, we 
went back to our data and we examined the sarcomere length of fixed cells on both glass 
and physiological stiffness hydrogels (10 kPa). This is not necessarily the same as the 
diastolic sarcomere length, since accurately determining sarcomere length would require 
live cell imaging of cells containing a fluorescent sarcomeric reporter (which would need 
to be engineered into the cell line).  Based on our analysis, we see that the sarcomere 
length of R134G is longer on glass (p = 0.004), but not significantly different on 
hydrogels (p = 0.342). We now include this point (lines 261-263) and methods describing 
our analysis procedure (lines 712-713) in the paper and have added the data to Table 1 
and Figure 6. 
 
In terms of determining the number of sarcomeres, this was more challenging. We tried 
several approaches, including using the approach developed by Kit Parker’s lab (PMID: 
25733020). Unfortunately, the unique sarcomeric morphology of these cells (see Fig. 6), 
caused these algorithms to be less accurate. Qualitatively, the R134G cells are larger, but 
there also appear to be larger regions that lack sarcomeres compared to the WT cells. 
Based on these challenges, we do not feel comfortable drawing any firm conclusions 
about whether the R134G cells contain more sarcomeres. 
  
6) Line 302: I think two log units for physiological calcium transients is too large of a range. 
Calcium fluctuations in intact cardiac myocytes is in the range of 0.1 - 1 microM. 
 
We agree that pCa 6-7 is a better representation of the range of calcium concentrations 
during a transient and have updated the manuscript accordingly. 
  
7) Lines 340-342: the following reference should be added to the sentence that describes TnT 
interaction with tropomyosin filaments on both side of the filament: Proc Natl Acad Sci U S A. 
2021 Mar 30;118(13):e2024288118. doi: 10.1073/pnas.2024288118. 
 
We agree and have added the suggested reference, which was not available at the time of 
initial submission. 
  
8) It is difficult to reconcile increased TF calcium binding affinity with impaired tropomyosin 
position to more active state. Is it possible that the R134G troponin complex is dissociating from 
actin-tropomyosin during the calcium titrations since troponin complex has a higher calcium 
binding affinity compared to TF? 
 
R134G TnT has an increased affinity for actin-tropomyosin relative to WT (Gangadharan 
et al., 2017), suggesting that it would be unlikely for the R134G troponin to dissociate 
from actin-tropomyosin to a greater extent than WT troponin. Moreover, we do not 
believe that the R134G troponin complex is dissociating from actin-tropomyosin in our 
experiments because we observe calcium-based regulation in our other molecular-level 
measurements.  
 
We believe that the most likely mechanism involved is partial uncoupling of calcium 
binding to troponin C from tropomyosin movement along the thin filament. The concept 
that cardiomyopathy mutations in the troponin T tail region can allosterically affect 
calcium binding and/or the coupling between the troponin complex and tropomyosin has 
been proposed by the Tardiff group (e.g., PMID: 26957598 and PMID: 31387947). Based 
on this mechanism, a reduction in coupling would mean that more calcium binding to 
troponin C would be required to reach the same level of thin filament activation, 
consistent with our results. We have expanded our discussion of this point on lines 309-
319, as detailed in the response to Reviewer 1. 
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Dear Dr. Greenberg, 
Thank you for the comprehensive revision of your manuscript . I am delighted to say it  can be
accepted for publicat ion at  MBoC. Thanks very much for submit t ing this study to our journal. I'm
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Dear Dr. Greenberg: 
Congratulat ions on the acceptance of your manuscript . 
A PDF of your manuscript  will be published on MBoC in Press, an early release version of the journal,
within 10 days. The date your manuscript  appears at  www.molbiolcell.org/toc/mboc/0/0 is the official
publicat ion date. Your manuscript  will also be scheduled for publicat ion in the next available issue of
MBoC. 
Within approximately four weeks you will receive a PDF page proof of your art icle. 
Your paper is among those chosen by the Editorial Board for Highlights from MBoC. Hight lights from
MBoC appears in the ASCB Newslet ter and highlights the important art icles from the most recent
issue of MBoC. 
All Highlights papers are also considered for the MBoC Paper of the Year. In order to be eligible for
this award, however, the first  author of the paper must be a student or postdoc. Please email me to
indicate if this paper is eligible for Paper of the Year. 
Would you like to see an image related to your accepted manuscript  on the cover of MBoC? Please
contact  the MBoC Editorial Office at  mboc@ascb.org to learn how to submit  an image. 
Authors of Art icles and Brief Communicat ions are encouraged to create a short  video abstract  to
accompany their art icle when it  is published. These video abstracts, known as Science Sketches,
are up to 2 minutes long and will be published on YouTube and then embedded in the art icle
abstract . Science Sketch Editors on the MBoC Editorial Board will provide guidance as you prepare
your video. Informat ion about how to prepare and submit  a video abstract  is available at
www.molbiolcell.org/science-sketches. Please contact  mboc@ascb.org if you are interested in
creat ing a Science Sketch. 
We are pleased that you chose to publish your work in MBoC. 
Sincerely, 
Eric Baker 
Journal Product ion Manager 
MBoC Editorial Office 
mbc@ascb.org 
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